1 |
CSF2
| 6件: Natural killer cell mediated cytotoxicity Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Shigellosis, Transcriptional misregulation in cancer, Rheumatoid arthritis | D11343
D11343
|
Otilimab
| 1件: 46 46 |
2 |
FYN
| 9件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Phospholipase D signaling pathway, Osteoclast differentiation, Platelet activation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Prion disease, Pathogenic Escherichia coli infection, Viral myocarditis | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
3 |
FYN
| 9件: Sphingolipid signaling pathway Sphingolipid signaling pathway, Phospholipase D signaling pathway, Osteoclast differentiation, Platelet activation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Prion disease, Pathogenic Escherichia coli infection, Viral myocarditis | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
4 |
IFNA1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
5 |
IFNA1
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
6 |
IFNA2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
7 |
IFNA2
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
8 |
IFNA4
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
9 |
IFNA4
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
10 |
IFNA5
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
11 |
IFNA5
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
12 |
IFNA6
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
13 |
IFNA6
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
14 |
IFNA7
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
15 |
IFNA7
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
16 |
IFNA8
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
17 |
IFNA8
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
18 |
IFNA10
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
19 |
IFNA10
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
20 |
IFNA13
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
21 |
IFNA13
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
22 |
IFNA14
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
23 |
IFNA14
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
24 |
IFNA16
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
25 |
IFNA16
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
26 |
IFNA17
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
27 |
IFNA17
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
28 |
IFNA21
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09662
D09662
|
Rontalizumab
| 1件: 49 49 |
29 |
IFNA21
| 8件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Tuberculosis, Pathways in cancer | D09668
D09668
|
Sifalimumab
| 1件: 49 49 |
30 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
31 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
32 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
33 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
34 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
35 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
36 |
IFNAR1
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
37 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D00745
D00745
|
Interferon alfa-2a
| 1件: 56 56 |
38 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D00746
D00746
|
Interferon beta-1b
| 1件: 13 13 |
39 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D02745
D02745
|
Interferon alfa-2b
| 2件: 25 25, 34 |
40 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D03305
D03305
|
Interferon alfa
| 6件: 13 13, 25, 26, 28, 56, 96 |
41 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D04554
D04554
|
Interferon beta-1a
| 4件: 13 13, 26, 96, 97 |
42 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D10483
D10483
|
Peginterferon beta-1a
| 1件: 13 13 |
43 |
IFNAR2
| 7件: PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Pathways in cancer | D11082
D11082
|
Anifrolumab
| 3件: 46 46, 49, 53 |
44 |
IFNG
| 15件: Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04242
D04242
|
Fontolizumab
| 1件: 46 46 |
45 |
IFNG
| 15件: Proteasome Proteasome, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D11120
D11120
|
Emapalumab
| 3件: 49 49, 65, 107 |
46 |
IFNGR1
| 9件: Necroptosis Necroptosis, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00747
D00747
|
Interferon gamma-1b
| 7件: 18 18, 65, 85, 228, 299, 301, 326 |
47 |
IFNGR2
| 9件: Necroptosis Necroptosis, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00747
D00747
|
Interferon gamma-1b
| 7件: 18 18, 65, 85, 228, 299, 301, 326 |
48 |
ITGAL
| 7件: Rap1 signaling pathway Rap1 signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Rheumatoid arthritis, Viral myocarditis | D03959
D03959
|
Efalizumab
| 9件: 11 11, 13, 37, 46, 49, 53, 61, 95, 96 |
49 |
LCK
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D03658
D03658
|
Dasatinib
| 2件: 51 51, 85 |
50 |
LCK
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | D06414
D06414
|
Dasatinib
| 2件: 51 51, 85 |
51 |
PIK3CA
| 39件: Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11011
D11011
|
Alpelisib
| 1件: 138 138 |
52 |
PIK3CA
| 39件: Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
53 |
PIK3CB
| 39件: Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
54 |
PIK3CD
| 39件: Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11158
D11158
|
Leniolisib
| 2件: 53 53, 65 |
55 |
PIK3CD
| 39件: Platinum drug resistance Platinum drug resistance, Ras signaling pathway, Rap1 signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Platelet activation, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Spinocerebellar ataxia, Prion disease, Shigellosis, Salmonella infection, Yersinia infection, Pathways in cancer, Viral carcinogenesis, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Small cell lung cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11437
D11437
|
Parsaclisib
| 3件: 35 35, 53, 61 |
56 |
PPP3CA
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
57 |
PPP3CA
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
58 |
PPP3CA
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
59 |
PPP3CA
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
60 |
PPP3CA
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
61 |
PPP3CB
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
62 |
PPP3CB
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
63 |
PPP3CB
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
64 |
PPP3CB
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
65 |
PPP3CB
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
66 |
PPP3CC
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
67 |
PPP3CC
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
68 |
PPP3CC
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
69 |
PPP3CC
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
70 |
PPP3CC
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
71 |
PPP3R1
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
72 |
PPP3R1
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
73 |
PPP3R1
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
74 |
PPP3R1
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
75 |
PPP3R1
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
76 |
PPP3R2
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00107
D00107
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
77 |
PPP3R2
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D00184
D00184
|
Cyclosporine
| 44件: 11 11, 19, 20, 26, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 55, 56, 58, 60, 61, 62, 63, 64, 65, 90, 93, 95, 97, 107, 113, 162, 164, 222, 226, 228, 234, 269, 274, 283, 284, 285, 302, 326 |
78 |
PPP3R2
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D05480
D05480
|
Pimecrolimus
| 1件: 160 160 |
79 |
PPP3R2
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08556
D08556
|
Tacrolimus
| 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
80 |
PPP3R2
| 14件: Oocyte meiosis Oocyte meiosis, Wnt signaling pathway, VEGF signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Oxytocin signaling pathway, Renin secretion, Prion disease, Pathways of neurodegeneration - multiple diseases, Tuberculosis, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09033
D09033
|
Voclosporin
| 2件: 49 49, 222 |
81 |
PRKCB
| 23件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, NF-kappa B signaling pathway, Phosphatidylinositol signaling system, Sphingolipid signaling pathway, Vascular smooth muscle contraction, Wnt signaling pathway, VEGF signaling pathway, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Retrograde endocannabinoid signaling, Serotonergic synapse, Thyroid hormone synthesis, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Parathyroid hormone synthesis, secretion and action, Salivary secretion, Pancreatic secretion, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Non-small cell lung cancer | D11935
D11935
|
Enzastaurin
| 1件: 168 168 |
82 |
MAP2K1
| 35件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
83 |
MAP2K1
| 35件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
84 |
MAP2K1
| 35件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
85 |
MAP2K1
| 35件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
86 |
MAP2K1
| 35件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, Oocyte meiosis, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Osteoclast differentiation, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
87 |
MAP2K2
| 28件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D09666
D09666
|
Selumetinib
| 1件: 34 34 |
88 |
MAP2K2
| 28件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10175
D10175
|
Trametinib
| 4件: 2 2, 34, 279, 280 |
89 |
MAP2K2
| 28件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10405
D10405
|
Cobimetinib
| 1件: 280 280 |
90 |
MAP2K2
| 28件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D10604
D10604
|
Binimetinib
| 1件: 34 34 |
91 |
MAP2K2
| 28件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Toll-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Regulation of actin cytoskeleton, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Yersinia infection, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Prostate cancer, Thyroid cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D11675
D11675
|
Mirdametinib
| 1件: 34 34 |
92 |
RAF1
| 30件: Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Sphingolipid signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Vascular smooth muscle contraction, VEGF signaling pathway, Signaling pathways regulating pluripotency of stem cells, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Thyroid hormone signaling pathway, Oxytocin signaling pathway, Relaxin signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Salmonella infection, Tuberculosis, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Non-small cell lung cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
93 |
BRAF
| 16件: Rap1 signaling pathway Rap1 signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer | D08524
D08524
|
Sorafenib
| 2件: 34 34, 86 |
94 |
BRAF
| 16件: Rap1 signaling pathway Rap1 signaling pathway, Vascular smooth muscle contraction, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Serotonergic synapse, Regulation of actin cytoskeleton, Progesterone-mediated oocyte maturation, Parathyroid hormone synthesis, secretion and action, Pathways of neurodegeneration - multiple diseases, Pathways in cancer, Proteoglycans in cancer, Renal cell carcinoma, Pancreatic cancer, Prostate cancer, Thyroid cancer, Non-small cell lung cancer | D10064
D10064
|
Dabrafenib
| 1件: 34 34 |
95 |
SYK
| 9件: NF-kappa B signaling pathway NF-kappa B signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Osteoclast differentiation, Platelet activation, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Tuberculosis, Viral carcinogenesis | D09347
D09347
|
Fostamatinib
| 4件: 46 46, 49, 61, 66 |
96 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00742
D00742
|
Etanercept
| 16件: 15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 |
97 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D00754
D00754
|
Thalidomide
| 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
98 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D01583
D01583
|
Pirfenidone
| 11件: 13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 |
99 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02597
D02597
|
Adalimumab
| 17件: 19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 |
100 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D02598
D02598
|
Infliximab
| 27件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
101 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D03441
D03441
|
Certolizumab pegol
| 8件: 37 37, 46, 49, 96, 97, 107, 226, 271 |
102 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04358
D04358
|
Golimumab
| 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
103 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D04687
D04687
|
Lenalidomide
| 8件: 16 16, 26, 28, 34, 49, 284, 300, 331 |
104 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D05393
D05393
|
Pegsunercept
| 1件: 46 46 |
105 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D08976
D08976
|
Pomalidomide
| 5件: 28 28, 51, 85, 227, 331 |
106 |
TNF
| 27件: Viral protein interaction with cytokine and cytokine receptor Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, T cell receptor signaling pathway, TNF signaling pathway, Type II diabetes mellitus, Non-alcoholic fatty liver disease, Type I diabetes mellitus, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Yersinia infection, Toxoplasmosis, Tuberculosis, Proteoglycans in cancer, Systemic lupus erythematosus, Rheumatoid arthritis | D09944
D09944
|
Ozoralizumab
| 1件: 46 46 |